Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide–based 3-or 4-drug regimen for …

J Van Wyk, F Ajana, F Bisshop, S De Wit… - Clinical Infectious …, 2020 - academic.oup.com
Background The 2-drug regimen dolutegravir (DTG)+ lamivudine (3TC) is indicated for
treatment-naive adults with human immunodeficiency virus type 1 (HIV-1). We present …

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label …

H Jaeger, ET Overton, G Richmond, G Rizzardini… - The Lancet …, 2021 - thelancet.com
Background Long-acting cabotegravir and rilpivirine administered monthly or every 2
months might address the challenges associated with daily oral antiretroviral therapy. The …

Efficacy and safety of switching to dolutegravir/lamivudine versus continuing a tenofovir alafenamide–based 3-or 4-drug regimen for maintenance of virologic …

O Osiyemi, S De Wit, F Ajana, F Bisshop… - Clinical Infectious …, 2022 - academic.oup.com
Background Switching to dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing
tenofovir alafenamide (TAF)–based regimens for maintaining virologic suppression at week …

Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults

CE Sloan, K Champenois, P Choisy, E Losina… - Aids, 2012 - journals.lww.com
Objective: To determine the component costs of care to optimize treatment with limited
resources. Design: We used the Cost-Effectiveness of Preventing AIDS Complications …

Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre …

D Rey, L Piroth, MJ Wendling, P Miailhes… - The Lancet Infectious …, 2015 - thelancet.com
Background Revaccination with double-dose hepatitis B vaccine has been recommended in
HIV-infected patients who do not respond to standard vaccination, but has not yet been …

[HTML][HTML] Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study–2012–2015

D Raben, AK Sullivan, A Mocroft, G Kutsyna… - PLoS …, 2019 - journals.plos.org
Background It is cost-effective to perform an HIV test in people with specific indicator
conditions (IC) with an undiagnosed HIV prevalence of at least 0.1%. Our aim was to …

[HTML][HTML] Chagas disease, France

FX Lescure, A Canestri, H Melliez… - Emerging infectious …, 2008 - ncbi.nlm.nih.gov
Chagas Disease, France - PMC Back to Top Skip to main content NIH NLM Logo Access keys
NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text …

[HTML][HTML] Brief report: improvement in metabolic health parameters at week 48 after switching from a tenofovir alafenamide–based 3-or 4-drug regimen to the 2-drug …

J van Wyk, M Ait-Khaled, J Santos… - JAIDS Journal of …, 2021 - journals.lww.com
Background: In TANGO, switching to dolutegravir/lamivudine was noninferior at 48 weeks to
continuing 3-/4-drug tenofovir alafenamide–based regimens in virologically suppressed …

Vaccination Against Hepatitis B Virus (HBV) in HIV-1–Infected Patients With Isolated Anti–HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study

L Piroth, O Launay, ML Michel… - The Journal of …, 2016 - academic.oup.com
Background. Although an isolated anti–hepatitis B virus (HBV) core antibody (anti-HBc)
serological profile is frequent in human immunodeficiency virus (HIV)–infected patients, data …

Antibodies to tetanus, diphtheria and pertussis among healthy adults vaccinated according to the French vaccination recommendations

O Launay, C Toneatti, C Bernède, E Njamkepo… - Human …, 2009 - Taylor & Francis
In this sero-epidemiological study, we investigated humoral immunity to three vaccine-
preventable diseases—tetanus, diphtheria and pertussis—among 331 adults (aged 18–60 …